Use of brain perfusion SPECT to determine responder to choline esterase inhibitor to reduce national therapeutic cost

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20140901001

Enrollment

Unknown

Registered

2014-09-01

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Screening

mild to moderate Alzheimer&#39

s disease

Eligibility

Sex/Gender

All

Age

50 Years to 0 Years

Inclusion criteria

Inclusion criteria: Diagnosis of probable Alzheimer's disease by NINCDS/ADRDA criteria, mild to moderate degree

Exclusion criteria

Exclusion criteria: Severe head trauma, delirium, depression, other known neuro-psychologic diseases, COPD, asthma, sik sinus syndrome, ischemic heart disease, peptic ulcer, history of gastrointestinal bleeding, type I DM, had received choline esterase inhibitors or nicergoline or other research drugs within 1 month before the study, alcohol or drug abuse, during treatment with NSAIDs, anticholinergic, carrbamazepine, dexamethasone, phenobarbital, ketoconazole

Design outcomes

Primary

Measure	Time frame
cognitive function 0,3,6 months cognitive battery tests	—

Secondary

Measure	Time frame
brain perfusion SPECT change 0,4 hr, 15 days, 3 months brain perfusion SPECT	—

Countries

THAILAND

Contacts

Public ContactSupatporn Tepmongkol

Faculty of Medicine, Chulalongkorn University

supatporn@hotmail.com022564283

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026